352431-33-5

352431-33-5 structure

Name: Triamcinolone acetonide-d6
Chemical Name: (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-Fluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8,8-bis[(2H3)methyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
CAS Number: 352431-33-5
Molecular Formula: C₂₄H₂₅D₆FO₆
Molecular Weight: 440.53
Catalog: Signaling Pathways GPCR/G Protein Glucocorticoid Receptor
Create Date: 2018-07-01 13:55:27
Modify Date: 2024-01-02 17:27:02
Triamcinolone acetonide-d6 is deuterium labeled Triamcinolone acetonide.

Name	(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-Fluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8,8-bis[(2H3)methyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
Synonyms	(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-4b-Fluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8,8-bis[(2H3)methyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxo l-2-one 2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one, 4b-fluoro-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-5-hydroxy-6b-(2-hydroxyacetyl)-4a,6a-dimethyl-8,8-di(methyl-d3)-, (4aS,4bR,5S,6aS,6bS,9a R,10aS,10bS)-

Description	Triamcinolone acetonide-d6 is deuterium labeled Triamcinolone acetonide.
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. http://en.wikipedia.org/wiki/Triamcinolone_acetonide [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [3]. Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391.